Exemplis Discimus 2012, 156(3):200-203

Nulla eget ligula vel elit bibendum facilisis.

Mili Evas, Zsu Dorien
National Institute of Microbiology, Arkanis Teaching Hospital, Mustafar Republic

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas nec erat sed risus accumsan faucibus.. Morbi justo diam, hendrerit mollis, tempus et, dapibus quis, leo. Sed id tortor faucibus tortor mollis sagittis. Donec vehicula nisi ut pede ultrices suscipit.. Ut nisi ipsum, aliquet eget, varius in, gravida quis, turpis. Etiam pede neque, porttitor eu, rhoncus et, sodales et, ligula. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Methods: Aliquam auctor, nibh vel congue congue, velit mi vulputate libero, vitae fringilla massa ipsum id risus. Sed ornare, risus in ultricies gravida, dui metus posuere purus, non tempus erat neque quis mauris.

Results: Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Etiam fringilla gravida massa. Nulla varius, felis quis consectetuer posuere, orci quam laoreet est, eget pharetra felis felis vitae orci.

Conclusions: Morbi pede eros, laoreet in, varius vel, ultricies vitae, justo. Pellentesque elit nunc, consectetuer scelerisque, ornare ac, tempor a, velit. Sed pede metus, imperdiet sed, accumsan ut, vehicula sit amet, velit. Nulla varius est at ligula interdum pellentesque. Fusce risus urna, dignissim a, convallis vel, volutpat sit amet, nunc. Duis blandit metus sit amet nulla lacinia pharetra. Morbi nisl turpis, fermentum vitae, consectetuer id, sodales ut, sem. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Kľúčové slová: Duis pretium

Vložený: September 8, 2011; Přijatý: April 13, 2012; Uverejnené online: June 1, 2012; Uverejnené: September 1, 2012 

Zobraziť celý článok

Referencie

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA: A Cancer Journal for Clinicians 2008;58:71-96. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003;21:3016-24. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A,Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3543-51. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, Pignon JP. Second or third additional chemo­therapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;4:CD004569. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocrine-Related Cancer 2005;12(3):533-48. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Molecular Cancer Therapeutics 2006;5(6):1396-1404. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998;8:283-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  8. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. A. Crossstudy comparison of gene expression studies for the molecular classification of lung cancer. Clinical Cancer Research 2004;10:2922-7. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH, Nevins JR. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New England Journal of Medicine 2006;355:570-80. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Carmen J, Marsit CJ, Liu M, Nelson HH , Posner M, Suzuki M, and Kelsey K T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23,1000-4. Prejsť k pôvodnému zdroju...
  11. Lee M, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, Wang YC. Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non-Small Cell Lung Cancer. Clinical Cancer Research 2007;13:832-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of non small cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008;6:1325-36. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  13. Damsma GE, Alt A, Brueckner F, Carell T, Cramer P. Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nature Structural and Molecular Biology 2007;12:1127-33. Prejsť k pôvodnému zdroju...
  14. Basu A, Krishnamurthy S. Cellular Responses to cisplatin-induced DNA damage. Journal of nucleic acids 2010;2010:1-16. doi:10.4061/2010/201367 Prejsť k pôvodnému zdroju...
  15. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development 2000;14:927-39.
  16. Yang ES, Xia F. BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS Journal 2010;277(15):3079-85. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  17. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Quralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics2004;13(20):2443-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki MM, Staphopoulos E, Georgoulias V, Rosell R , Souglakos J. Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. PLoS ONE2008;3(11):e3695. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Wang L, Wei J, Qian X, Yin H, ZhaoY, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008;8:97. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  20. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida F, Farabi R, Jassem J. BRCA1: a novel prognostic factor in resected nonsmall-cell lung cancer;. PLoS One2007;2:e1129. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  21. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, Penas R, Catot S, Isla D, JM Sanchez, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M. Customized treatment in nonsmallcell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One2009;4:e5133. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  22. Tiseo M, Bordi P, Bortesi B. ERCC 1/BRCA1 protein expressions and ERCC1/ XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin. Journal of Thoracic Oncol 2009;4:D7.5.
  23. Wachtersa FM, Wong LSM. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Shuji Ota, Genichiro Ishii, Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.. Lung Cancer 2009;64:98-104. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Kanga CH, Jangb BG, Kimc DW, Chungb DH, Kima YT, Jheond S, Sungd CW, Kima JH. The prognostic significance of ERCC1, BRCA1, XRCC1, and βIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer2010; 68(3):478-83. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah